Accueil
Neuratris
Programmes de recherche
L’offre de NeurATRIS
Les outils en quelques mots
Les outils par pathologie
Un continuum en recherche translationnelle
Modalités de collaboration
Soumettre un projet en ligne
Projets et collaborations phares
Pre-clinical assessment of pluripotent stem cell therapy for Huntington’s disease
REPAIR-HD : Human pluripotent stem cell differenciation, safety and preparation for therapeutic transplantation in Huntington's disease
Muticentric intra-cerebral grafting in Huntington’s disease
Hematopoietic stem cell gene therapy in X-linked adrenoleukodystrophy
Hematopoietic stem cell gene therapy with lentiviral vector in RETT syndrome
A phase I/II, Open Labeled, Monocentric gene therapy Study in Children with Metachromatic Leukodystrophy
Brain gene therapy with AAVrh10 encoding human CYP46A1 in inherited forms of Alzheimer and Tauopathie
Targeting therapeutic genes to oligodendrocytes in brain and spinal cord
Gene therapy for Huntington’s disease using LV-CNTF
Optimization of intrathecal delivery of various AAV vectors
PROSAVIN Dopamine gene based treatment for Parkinson's disease
DopaGen
Assessing neurodegeneration, intracellular viscosity and molecular crowding in vivo using diffusion-weighted and proton/phosphorus NMR spectroscopy
Development & characterization of a primate model of periventricular leucomalasia
Imaging CNS demyelination and remyelination in Multiple Sclerosis using PET
Microglial activation in Parkinson’s Disease
HDeNERGY : Validation of molecular neuroimaging biomarkers in Huntington's disease in view of therapeutic trials targeting the Krebs cycle
PRIMA-TAU. A primate model of tauopathies
A primate model of Huntington’s disease and the assessment of Si-RNA therapy
ASTROinAD : Towards a gene therapy targeting astrocytes in AD
LRRK2 : Etude de la neurotoxicité des domaines fonctionnels de LRRK2 par vectorisation virale
LRRK2 and alpha-synucléine : Fonctionnal interaction between LRRK2 and in vivo alpha-synucléine
Inductibility of amyloidosis and Tau pathologies in Alzheimer's disease : Feasability ans mechanisms of action in a non human primate model
New tools for the diagnosis of Alzheimer's disease : LLAMA VHH antibody fragments targeting amyloid plaques and neurofibrillary lesions (LLAMALZ)
Nucleipark
LRRK2 prospective cohort: identifying pre-symptomatic markers in Parkinson’s
Study of S47445 in a rat model of Huntington's disease
SCREENTOX:Stem Cells for Replicable Efficient Extended and Normalized Toxicology
Study of S47445 in a primate model of Huntington's disease
The blood brain barrier in perinatal brain damage
Rare infantile epilepsies: use of clinical trial simulation for the choice and optimization of study design
In vitro study of the human blood brain barrier at pediatric age
Impact du stress foetal sur la santé mentale : les facteurs HSF (Heat Shck Fcators), médiateurs d'événements épigénétiques
Validate an immunoassay based on electro-chemo-luminescence to measure cytokine levels in human plasma in indviduals with psychiatric disorders
Role of microglial metabolism in perinatal inflammation
Rôle de l'inflammation périnatale dans la physiopathologie des troubles du spectre autistique
EATRIS
Newsroom
Calendrier
はじめに
English version
Aller au contenu
Aller au menu principal et à l'identification
Navigation de recherche
Navigation
Recherche
Accueil
>
L’offre de NeurATRIS
>
Projets et collaborations phares
>
New tools for the diagnosis of Alzheimer's disease : LLAMA VHH antibody fragments targeting amyloid plaques and neurofibrillary lesions (LLAMALZ)
.
JavaScript is currently disabled.
Please enable it for a better experience of
Jumi
.
